Clinical Trials
3 trialsNCT06833073 2026-05-28
INTerpath-011
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT05037279 2026-03-20
EVER
Verity Pharmaceuticals Inc.
Phase 3 Recruiting
NCT06187506 2024-07-12
Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer
Fudan University
Phase 2 Recruiting